Glucagon-stimulated copeptin measurements in the differential diagnosis of diabetes insipidus: a double-blind, randomized, placebo-controlled study

What Was Tested

Researchers studied Glucagon in this randomized controlled trial publication.

The primary objective was to determine whether glucagon stimulates copeptin and to explore whether the copeptin response differentiates between diabetes insipidus and primary polydipsia.

Why It Was Studied

The differential diagnosis of diabetes insipidus is challenging.

Who Took Part

The abstract describes 22 participants taking part.

Double-blind, randomized, placebo-controlled trial including 22 healthy participants, 10 patients with central diabetes insipidus, and 10 patients with primary polydipsia at the University Hospital Basel, Switzerland.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this Glucagon study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Glucagon, so expectations could not easily colour the readings.

Some participants received a placebo instead of Glucagon, giving a reference point.

Copeptin levels were measured at baseline, 30, 60, 90, 120, 150, and 180 min after injection.

What Was Measured

PubMed files the paper under topics including Arginine, Diabetes Insipidus, Diabetes Mellitus, Diagnosis, Differential, Glucagon, Glycopeptides and Growth Hormone.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Glucagon in 22 participants.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2022 (European journal of endocrinology), a journal based in England.

More context: the Glucagon compound page, all human trials.